- Home
- TCRX vs MBAI Comparison
TCRX vs MBAI Comparison
Compare TCRX & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCRX | MBAI |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 49.1M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TCRX | MBAI |
|---|---|---|
| Price | $0.19 | $1.97 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 579.6K | 17.1K |
| Earning Date | 11-11-2026 | 11-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | $103.86 |
| Revenue Next Year | N/A | $231.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.18 | $0.95 |
| 52 Week High | $2.14 | $10.21 |
Technical Indicators
Market Signals| Indicator | TCRX | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 27.68 | 23.73 |
| Support Level | N/A | $1.33 |
| Resistance Level | $0.37 | $2.05 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 14.81 | 3.49 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About MBAI Check-Cap Ltd. Ordinary Share
MBody AI Ltd develops enterprise software to deploy and manage autonomous robot workforces for hospitality and gaming operators. The Company's proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI serves Fortune 500 operators as customers.